Morningside Ventures, IAG Capital Partners and Starbloom Capital led the round. New investors New Vintage, Apollo Health Ventures and Benvolio Group also participated, among others.
The Series C comes less than three years after the company brought in $73 million in its Series B round.
Cambridge, Massachusetts–based Cognito says the financing strengthens its position as it advances toward the pivotal data readout, regulatory submission and commercial launch of its neurotechnology. It also supports the continued clinical development of Spectris, its non-invasive neuromodulation system.
The system delivers proprietary gamma frequency light and sound stimulation. This evokes EEG-confirmed gamma frequency brain oscillations to treat central nervous system (CNS) diseases. It restores brain electrical activity disrupted in Alzheimer’s.
Cognito said the Series C supports the expansion of its launch readiness efforts for Spectris ahead of its anticipated market entry in 2027. It also supports the advancement of Spectris into additional neurodegenerative indications. The company plans to pursue these through collaborations like one inked with WVU Rockefeller Neuroscience Institute in November 2025.
“With this financing, we are entering a pivotal moment for our company, and for the patients and families waiting for new options in Alzheimer’s disease,” said Christian Howell, CEO, Cognito Therapeutics. “Spectris has the potential to become the world’s first physician-prescribed, at-home neuroprotective therapy for patients diagnosed with Alzheimer’s, designed to preserve cognition and daily function. This funding allows us to make this therapy accessible to those who need it most.”
